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Background and Purpose: The effect of low molecular weight heparin (LMWH) in the management of cerebral 
venous thrombosis (CVT) remains unclear. The present study was performed to determine the safety and feasibility 
of subcutaneous LMWH, with particular attention to hemorrhagic conversions.
Methods: LMWH (nadroparin, 7,500 ICU, every 12 hours) was administered subcutaneously for 14 days to 12 
patients diagnosed with CVT. Initial clinical manifestations, etiologies and the clinical courses after LMWH treatment 
were also evaluated. Possible hemorrhagic side effects, including aggravation of the initial hemorrhage and/or newly 
developed-hemorrhagic conversions were monitored by image analysis.
Results:  Headaches  and  convulsive  movements  were  frequent  presenting  symptoms  for  CVT.  Clinical 
improvement was usually observed within 2 to 8 days after LMWH. Symptom stabilization was observed within 4 
to 60 days. Neither clinical aggravations, nor newly developed parenchymal lesions were observed during LMWH 
maintenance. Associated parenchymal lesions were observed in 9 of the 12 patients, 5 of which manifested with 
hemorrhagic conversion, as detected by image analysis. However, no clinical and radiologic aggravation was noted 
in these 5 patients. 
Conclusions: Our results suggest that LMWH may be safe and feasible in the management of CVT.
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INTRODUCTION
Clinical symptoms and signs of cerebral venous 
thrombosis (CVT) are extremely variable, and the 
diagnosis of CVT is thought to be under-recognized 
because of its nonspecific symptoms.
1 In the early 
angiographic era, CVT had a high (30-50%) mortality. 
However, CVT related deaths has been reduced consid-
erably (6.5-15%) with the advance of diagnostic tools 
such as computed tomography (CT) and magnetic 
resonance imaging (MRI), as well as early application of 
anticoagulants following diagnosis.
2
Unfractionated heparin has been the most common 
first-line drug for CVT,
3,4 but its use has been the 
subject of much controversy because of reported 
hemorrhagic complications.
2,5,6 The hemorrhagic conversion 
in the infarcted lesion is a major disincentive against the 
use of heparin. Low molecular weight heparin (LMWH) 
exerts an anticoagulant effect by inactivating factor Xa.
7 
LMWH also has a better antithrombotic-to-hemorrhagic 
ratio due to its low antithrombin effect.
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LMWH use has been shown to have no increase in 
bleeding risk during operation and post-operative 
drainage.
8,9 Additionally, several studies have equated 
the efficacy of LMWH with that of unfractionated 
heparin in the management of deep vein thrombosis,
10 
venous thromboembolism,
11 and unstable angina.
12,13 
Furthermore, LMWH has much better bioavailability, 
that is, a longer plasma half-life and less variable anti-
coagulation effect with a fixed dose than unfractionated 
heparin.
7
The numerous publications reporting the benefits of 
LMWH, particularly the antithrombotic effects and better 
bioavailability, suggest that LMWH can replace unfrac-
tionated heparin in the early treatment of CVT. The 
present study evaluates whether LMWH is safe, feasible, 
and perhaps a better first-line drug for CVT.
MATERIALS AND METHODS
1. Diagnosis of CVT
CVT was diagnosed using pre- and post-enhanced 
T1-weighted MRI (T1WI), CT, magnetic resonance 
venography, and/or cerebral angiography. The imaging 
study was performed at the time of hospital admission 
for initial diagnosis of CVT. To evaluate temporal 
changes to brain lesions, each patient was subjected to 
follow-up MRI and/or CT studies at discharge. Both 
direct and indirect signs of thrombosis in the intracranial 
venous system were used for the diagnosis of CVT. 
Direct evidence of CVT included thrombi in the cerebral 
vein and sinuses on any imaging modality.
2 Intensified 
venous collaterals, the presence of cork screw veins, 
broken bridging veins, venous dilatation, and delayed 
venous emptying were considered as indirect evidence 
for CVT.
2 Combined parenchymal lesions with hemor-
rhagic conversion were also confirmed by density or 
signal changes on CT, T1WI, and/or gradient echo 
images.
2 An increase in the initial hemorrhage size 
and/or newly developed bleeding detected follow-up 
imaging was categorized as an LMWH-related hemor-
rhagic complication.
2. Causes of CVT
To evaluate the causes of CVT in patients, we 
assessed a history of risk factors that have been reported 
to be associated with CVT, such as oral contraceptive, 
parturition, infectious disease, ear disease, carcinoma, 
dehydration, marasmus, sepsis, acute lymphoblastic 
leukemia, chemotherapy, systemic lupus erythematosus, 
Behςet's disease, osteoporosis, diabetes mellitus, homo-
cystinuria, and iron deficiency anemia.
14 Laboratory 
blood tests were also performed to determine the presence 
of coagulopathy, such as complete blood count (CBC), 
liver function test (LFT), prothrombin time (PT), activated 
partial thromboplastin time (aPTT), levels of protein C 
and S, antithrombin III, lupus anticoagulant, and anticar-
diolipin antibody. If the above historical and laboratory 
evaluation for CVT revealed no abnormality, we 
classified the case as not-determined etiology.
14
3. Management and clinical courses of CVT
Twice daily subcutaneous injection of 7,500 IU nadro-
parine (Fraxiparine
Ⓡ, Sanoffi-Aventis, France) immedi-
ately followed the initial CVT diagnosis and was 
maintained for 2 weeks. For secondary prevention after 
the termination of the drug, oral anticoagulant (warfarin) 
or antiplatelet agent (aspirin) was prescribed depending 
on the individual risk factors.
Initial manifestations were evaluated at CVT diagnosis 
and closely monitored for changes during nadroparine 
treatment until the initial neurological symptoms were 
normalized or stabilized. We recorded the onset of 
symptoms and/or signs prior to CVT diagnosis. We also 
recorded the interval from initial nadroparine treatment 
to initial evidence of clinical improvement. This interval 
time was used to estimate the drug's efficacy at managing 
CVT. Initial improvement was defined as the first signs 
of recovery from subjective symptoms observed at 
admission, such as headache or nausea, and/or objective 
neurological deficits, such as motor deficit, aphasia, and 
mental deterioration. Finally, the interval from initial 
nadroparin treatment to normalization or stabilization of 
initial neurological alterations was evaluated. Exacer-
bations of initial neurological deficits and/or newly Journal of Clinical Neurology: Vol. 1, No. 1, 2005
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Pt
Age/
Sex
Presenting 
Sx and Sn
Initial 
Assessment
Etiology
Start of 
therapy (days)*
Initial 
improvement 
(days)
†
Normalization 
or stabilization 
of symptom 
(days)
‡
Aggravation 
of clinical 
symptoms 
Sx Sn
13 1 / M H A ,  N / V H A ↓  protein C 11 11 2 4 -
2 59/M Mental change Tumor 
metastasis 
(stomach 
cancer)
ND 3 2 2 30 -
3 26/F Convulsion, 
sensory aphasia
Sz ↓  protein S 16 1 20 30 -
4 31/F Convulsion Sz Postpartum 2 2 6 36 -
5 21/F HA, N/V HA COM, ↓  protein C 
and S, IDA
30 2 8 60 -
6 53/F Convulsion, 
hemiparesis
Sz ND 1 1 2 11 -
7 51/F HA, hemianopsia Brain tumor ND 17 14 2 15 -
82 5 / F H A ,
convulsion
Sz Oral contraceptive 14 1 20 26 -
93 0 / M H A ,  N / V V i r a l  
encephalitis
↓  protein C, 
osteomyelitis
16 10 2 222 -
10 76/M HA, Rt. 
hemiparesis, 
global aphasia
Lt MCA 
infarction
↓  protein C, S 9 1 3 12 -
11 27/M HA, fever Meningitis ↓  protein C, S, 
↑  factor V
16 14 3 50 -
12 45/F HA, convulsion Sz ds ↓  protein S, 
↑  factor VIII
31 2 2 -
Pt: patient number, Sx: symptom, Sn: sign, HA: headache, N/V: nausea/vomiting, Sz: seizure disorder, MCA: middle cerebral artery, 
↓: deficiency of protein C or S, ↑: increased level of factor V and VIII, IDA: iron deficiency anemia, ND: not determined, COM: 
chronic otitis media, -: no aggravation of clinical symptoms, *interval from initial symptom to start of nadroparin, 
†interval from start 
of nadroparin to initial improvement of symptoms, 
‡interval from start of nadroparin to normalization and/or stabilization of symptoms.
Table 1. Presenting manifestations, etiology, and clinical courses after LMWH start in CVT patients
developed neurological deficits after treatment were 
classified as, “ineffective” or as, “side effect”.
RESULTS
1. Diagnosis of CVT
A total of 12 patients (male : female=5 : 7, age 21-76 
years) were included in the present study (Table 1). 
Thrombi were noted in the cerebral venous sinus of all 
patients, serving as a direct evidence of CVT (Table 2). 
The thrombi were located in multiple sinuses in five 
patients. The venous thrombi were most commonly in 
the transverse sinus, followed by the superior sagittal 
and sigmoid sinuses. Associated parenchymal venous 
infarction was observed in nine patients. The Kim JS, et al. Safety and Feasibility of Subcutaneous Low Molecular Weight Heparin for Cerebral Venous Sinus Thrombosis 
- 137 -
Pt Thrombus in sinus Parenchymal lesion
Hemorrhge on 
initial image
Follow-up parenchymal 
lesion
1
2
3
4
5
6
7
8
9
10
11
12
SSS, ISS. TS
ICV, STS
Lt. TS
Lt. TS
Lt. TS. SMS
SSS Lt. TS
Rt. TS
SSS
SSS STS, both TS
Lt. cortical vein
SSS, SMS, Rt. TS, DS
ICV, ISS
No
Both BG, thalamus
Lt. temporal
Lt. frontal, Rt parietal
No
Both parietal
Lt. parieto-occipital
Rt. Parietal
Lt. parietal. Rt parietal
Lt. fronto-parietal
No
Both BG, thalamus, centrum semiovale
No
No
Yes
No
No
No
Yes
Yes
Yes*
Yes
No
No
-
+
-
+
-
-
+
+
+
+
-
-
Pt: patient number, Lt.: left, Rt.: right, SSS: superior sagittal sinus, ICV: inferior cerebral vein, ISS: inferior sagittal sinus, TS: transverse 
sinus, SMS: sigmoid sinus, DS: dural sinus, BG: basal ganglia, frontal: frontal lobe, parietal: parietal lobe, occipital: occipital lobe, 
*hemorrhagic conversion after starting heparin, -: no remaining encephalomalatic change on follow-up image, +: remaining 
encephalomalatic change on follow-up image.
Table 2. Radiological findings on initial and follow-up brain imaging
parenchymal lesions were distributed in variable 
hemispheric regions, including the temporal, parietal, 
and occipital lobes. In patients 2 and 12, venous 
infarctions in deep structures, such as basal ganglia, 
thalami, and/or the centrum semiovale, were associated 
with the venous thrombi located in inferior cerebral 
veins (Table 2).
2. Causes of CVT
Common risk factors responsible for CVT were found 
in all but two patients (cases 6 and 7) (Table 1). Protein 
C and/or S deficiency were determined to be the most 
frequent cause, affecting 7 out of 12 patients. 
Deficiencies of both proteins were detected in three 
patients. Two patients had not only protein S and/or C 
deficiency, but also elevated levels of blood factor V 
(case 11) and blood factor VIII (case 12). Postpartum 
and oral contraceptives were checked in cases 4 and 8, 
respectively. Additionally, chronic otitis media in case 5 
and osteomyelitis in the left lower tibia in case 9 were 
associated with protein C and/or S deficiency. Iron 
deficiency anemia (Hb=7.3 gm/dl) was detected in case 
5. Case 2 had been diagnosed with stomach cancer 6 
months previously but had no abnormality on the 
evaluated history and laboratory work-up. In all patients, 
warfarin was maintained at levels 2 to 3 of the 
international normal range of prothrombine time for 
secondary prevention of CVT.
3. Clinical manifestations and courses of CVT
Headache was the most frequent presenting symptom, 
and associated with neurological deficits, such as 
convulsive movement, sensory or global aphasia, hemi-
paresis, and hemianopsia. However, convulsive movement 
was the dominant manifestation without the headache 
symptoms in three patients. A mental status of deep 
drowsiness was the presenting manifestation in case 2. 
Interestingly, before the availability of imaging diagnosis 
for CVT, the likely presumptive diagnosis for case 2 
was a seizure disorder. Other patients were initially 
determined as having variable diagnoses, with headaches 
in two patients, metastasis of stomach cancer, brain 
tumor, encephalitis, cerebral infarction, and meningitis 
(Table 1).
CVT was diagnosed rapidly (within 1 to 3 days) 
when the patients showed characteristic neurological Journal of Clinical Neurology: Vol. 1, No. 1, 2005
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Figure 1. Case 9. Heparin-induced hemorrhagic conversion on 
initial and follow-up images. (A) Absence of parenchymal lesion
on an initial CT scan, (B) marked thrombi in superior sagittal 
and straight sinus on initial enhanced T1WI, (C) hemorrhagic 
conversion on a follow-up non-enhanced CT scan after 2 days of
heparin treatment, and (D) remaining encephalomalatic lesion on
hemorrhagic converted lesion on a follow-up non-enhanced CT 
scan 2 months into treatment.
deterioration at the hospital. However, the diagnosis was 
usually delayed (11 to 30 days from the initial onset of 
symptoms), when the patient first suffered from 
non-specific neurological manifestations, such as head-
ache and nausea. Improvement of the initial symptoms 
was usually detected within 2 to 8 days after taking 
nadroparine, irrespective of a delay in the diagnosis of 
CVT. In two patients (case 3 and 8), improvement was 
detected after 20 days of nadroparine because clinical 
evaluations were impossible due to the inability to 
communicate. One patient showed sensory aphasia at 
admission, while another patient presented with a deep 
drowsiness during the management with nadroparine. 
Normalization to the previous neurological condition 
occurred rapidly in two patients, within 2 and 4 days in 
cases 1 and 12, respectively. Most patients normalized 
their initial neurological state within 11 to 60 days. 
Patient 9, who had marked thrombi and hemorrhagic 
conversion in both cerebral cortices, showed stabilization 
of right side hemiplegia by 222 days of nadroparine 
treatment, improving to Grade III.
4. Safety of LMWH for hemorrhagic-converted 
venous infarction
Hemorrhagic conversion was detected in five of the 
nine patients wth venous infarctions: cases 3, 7, 8, 9, 
and 10. In case 9, severe thrombi in the superior sagittal 
sinus, inferior sagittal sinus, and sigmoid sinus (Fig. 
1-B) and parenchymal lesion without hemorrhagic 
conversion were detected in the initial imaging study 
(Fig. 1-A), Unfractionated heparin was administered 
immediately following the CVT diagnosis, and 2 days 
later the mental state had decreased from alert to deep 
drowsiness. Motor weakness on the right extremities had 
also aggravated to hemiplegia. On the follow-up brain 
CT study, hemorrhagic conversion had developed in the 
previous infarcted lesions (Fig. 1-C). The mental state 
markedly improved 2 days after replacing heparin with 
nadroparin and no aggravation of clinical symptoms was 
detected during the maintenance with nadroparin.
Associated hemorrhage was observed in the initial 
brain image of four patients. Again, nadroparine did not 
cause clinical or radiological aggravation. In case 3, a 
marked temporal lobe hemorrhagic infarction was 
observed on the initial CT, (Fig. 2-A) and the left lateral 
sinus was evident in cerebral venography performed at 
admission. (Fig. 2-B) The initiation of nadroparine treat-
ment resulted in no aggravation of mental status, even 
though the surrounding edema increased in the follow-up 
study (Fig. 2-C). The patient recovered to an alert and 
cooperative status without neurological findings after 
termination of the nadroparine schedule. Encephalomalatic 
change at the hemorrhagic converted parenchymal lesion 
remained in case 9 (Fig. 1-D) and 4. (Fig. 2-D) Convul-
sive movement developed after hospital discharge in 
both of these patients, and an anti-epileptic drug was 
prescribed to prevent recurrence. Hemorrhagic-converted 
cerebral lesions were observed in the initial imaging 
study in three other patients. These patients showed 
clinical improvement after taking nadroparine, and no 
aggravation of the initial manifestations as well as 
radiological problems were observed. However, hemor-
rhagic converted lesions remained as encephalomalatic Kim JS, et al. Safety and Feasibility of Subcutaneous Low Molecular Weight Heparin for Cerebral Venous Sinus Thrombosis 
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Figure 2. Case 3. Hemorrhagic converted venous infarctions on
initial and follow-up images. (A) Hemorrhagic infarction in the 
left temporal lobe on initial image, (B) absence of left lateral
sinus on cerebral venography performed after admission, (C) 
increased surrounding edema without aggravation of initial 
hemorrhage on follow-up image after 7 days of nadroparin 
maintenance, and (D) remaining parenchymal destruction on a 
follow-up T2-weighted axial image, taken a year after treatment.
changes in the follow-up imaging studies.
DISCUSSION
The patients included in the present study showed 
improvement after taking LMWH without clinical aggra-
vation suggesting its general superiority over unfrac-
tionated heparin at managing CVT. Unfractionated 
heparin had been the preferred choice for anticoagulation 
of CVT, with many series demonstrating good clinical 
prognosis.
3,15,16 Recently, however, LMWH has been 
widely speculated as an alternative for managing and 
preventing venous thromboembolism with equal 
effectiveness.
17-20
Although unfractionated heparin may prevent the 
progression of thrombosis and further infarction, it 
required very careful administration because of its hemor-
rhagic side effects.
5,6 A previous randomized trial has 
shown that unfractionated heparin was both safe and 
effective at managing CVT.
3 However, the results had 
been debated due to the small sample size, questionable 
outcome criteria, and a long treatment delay.
21,22 In the 
present study, we also experienced clinical aggravation 
after initial heparin treatment in case 9, and newly 
developed hemorrhagic conversion was confirmed in the 
follow-up imaging study. Therefore, unfractionated 
heparin should be used with caution as a first-line drug 
for CVT patients.
LMWH presents a lower risk of bleeding than 
unfractionated heparin in the management of venous 
thromboembolism.
10 The probability of bleeding is not 
increased during the perioperative period of major 
surgeries when LMWH was used.
8,9 Therefore, LMWH 
would be expected to be a safe anticoagulant for 
managing CVT, especially for treating hemorrhage- 
converted venous infarctions. A previous randomized 
trial determined that LMWH was sufficiently safe for 
managing hemorrhagic converted CVT.
20 CVT patients 
included in the present study showed no evidence of 
LMWH-associated hemorrhage. Even if they present 
hemorrhagic conversion in the initial imaging studies, 
the initial manifestations improved rapidly after LMWH 
was administered without clinical or radiological 
aggravations. Patient 9 exhibited heparin-induced clinical 
and radiological aggravations, but the clinial manifes-
tations rapidly stabilized after an anticoagulation switch 
to LMWH. Therefore, the present study provides further 
supports for the safety of LMWH in managing CVT and 
venous thromboembolism.
Unfractionated heparin presents other practical limita-
tions, such as a narrow window of therapeutic time, less 
predictable kinetics, platelet activation, and the inability 
to inhibit clot-bound thrombin.
23 Consequently, unfrac-
tionated heparin requires frequent laboratory monitoring 
and close observation to prevent heparin-induced compli-
cations.
24 On the other hand, LMHW has better bioavail-
ability, limited non-specific binding, and non-dose- 
dependent half-life, as well as the ease of subcutaneous 
injections without laboratory monitoring.
7 In several 
other studies, LMWH performed similarly, if not better, 
at preventing and managing both venous thromboem-
bolism and CVT.
17-20 Furthermore, the convenient Journal of Clinical Neurology: Vol. 1, No. 1, 2005
- 140 -
subcutaneous injection without laboratory monitoring 
makes LMWH a better first-line CVT drug than 
unfractionated heparin.
25,26
The ideal LMWH regimen for CVT has not yet been 
established, even though its efficacy and safety have 
been widely reported for venous thromboembolism and 
CVT. Long-term LMWH treatments (up to 3 months) 
are reportedly effective at managing symptomatic venous 
thromboembolism.
27 Other studies have shown that short 
term LMWH treatments (5 to 7 days) was effective at 
treating thromboprophylaxis.
28,29 Two weeks of LMWH 
maintenance was recently recommended for the prevention 
of venous thromboembolism.
19 For CVT, however, 
LMWH was administered twice a day for 3 weeks in a 
randomized trial.
20 In the present study, administration of 
LMWH twice a day for 2 weeks produced clinically 
acceptable results. Therefore, 2 weeks might be 
sufficient for CVT or thromboembolism management, 
although additional trials are required to verify the 
appropriate daily dosage and duration of LMWH main-
tenance.
In conclusion, LMWH was found to be safe and 
effective for managing CVT. The small number of tested 
patients and the lack of a control group receiving 
unfractionated heparin limit the applicability of our data. 
However, the rapid improvements without clinical or 
radiological aggravations strongly support previous studies 
showing the safety and efficacy associated with LMWH, 
and hence its potential as a better first-line agent for 
treating hemorrhagic converted CVT patients.
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